Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis
Open Access
- 18 August 2025
- journal article
- microbiology
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 19 (8) , e0013393
Abstract
Introduction: Shigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting. Methods: We conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present. Results: This review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6- 5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.Keywords
All Related Versions
Funding Information
- Gates Foundation (INV-033228)
This publication has 65 references indexed in Scilit:
- Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030EBioMedicine, 2024
- The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshopsVaccine, 2023
- Shigellosis in Southeast Asia: A systematic review and meta-analysisTravel Medicine and Infectious Disease, 2023
- Seriously misleading results using inverse of Freeman‐Tukey double arcsine transformation in meta‐analysis of single proportionsResearch Synthesis Methods, 2019
- Whole genome sequencing of Shigella sonnei through PulseNet Latin America and Caribbean: advancing global surveillance of foodborne illnessesClinical Microbiology and Infection, 2017
- The importance of integrons for development and propagation of resistance in Shigella: the case of Latin AmericaBrazilian Journal of Microbiology, 2016
- Randomized Double-Blind Controlled Trial of Bovine Lactoferrin for Prevention of Diarrhea in ChildrenThe Journal of Pediatrics, 2013
- Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1–4-year-old Israeli childrenVaccine, 2010
- Etiology of childhood diarrhea in the northeast of Brazil: significant emergent diarrheal pathogensDiagnostic Microbiology and Infectious Disease, 2010
- Rotavirus type A and other enteric pathogens in stool samples from children with acute diarrhea on the Colombian northern coastInternational Microbiology, 2003